Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database

被引:18
作者
Bejhed, Rebecca S. [1 ]
Kharazmi, Mohammad [2 ,3 ]
Hallberg, Par [4 ]
机构
[1] Uppsala Univ, Angstrom Lab, Uppsala, Sweden
[2] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden
[3] Cent Hosp Vasteras, Vasteras, Sweden
[4] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词
bisphosphonates; osteonecrosis; atypical fracture; adverse drug reaction; drug safety; pharmacovigilance; risk factor; MEDICATION-RELATED OSTEONECROSIS; BONE; PREVENTION; ONJ;
D O I
10.1177/1060028016649368
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ) are well-known adverse drug reactions (ADRs) associated with bisphosphonates. To prevent these ADRs and to aid in the search for pathogenic mechanisms, knowledge of risk factors can be helpful. Objective: To identify risk factors for bisphosphonate-related ONJ and AF. Methods: In this case-control study of reports of bisphosphonate-related ADRs from February 16, 1984, to October 16, 2013, in the Swedish national database of ADRs, we compared characteristics for cases of ONJ (n = 167) and AF (n = 55) with all other bisphosphonate-related ADRs (n = 565) with regard to demographic variables, clinical characteristics, and concomitant drug treatments. We adjusted for multiple comparisons with Bonferroni correction. Results: Time to onset of ADRs differed statistically significantly between cases of AF and controls (2156 vs 111 days). For ONJ versus controls, differences were statistically significant for time to onset (1240 vs 111 days), intravenous administration (40% vs 20%), dental procedures (49% vs 0.2%) and prostheses (5% vs 0%), cancer disease (44% vs 12%), multiple myeloma (21% vs 1%), rheumatoid arthritis (14% vs 5%), and treatment with antineoplastic agents and oxycodone. Conclusion: These results lend further evidence to previously identified risk factors for ONJthat is, intravenous bisphosphonate administration; invasive dental procedures and dental prostheses; cancer disease, in particular multiple myeloma; and possibly, long-term bisphosphonate treatment. A putative further risk factor is rheumatoid arthritis. Only long-term bisphosphonate treatment was more common among AF cases. The lack of overlap of risk factors between ONJ and AF suggests different pathogenic mechanisms.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 35 条
[1]   Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].
Adler, Robert A. ;
El-Hajj Fuleihan, Ghada ;
Bauer, Douglas C. ;
Camacho, Pauline M. ;
Clarke, Bart L. ;
Clines, Gregory A. ;
Compston, Juliet E. ;
Drake, Matthew T. ;
Edwards, Beatrice J. ;
Favus, Murray J. ;
Greenspan, Susan L. ;
McKinney, Ross, Jr. ;
Pignolo, Robert J. ;
Sellmeyer, Deborah E. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35
[2]  
Berenson JR, 1999, ANNU REV MED, V50, P237
[3]   Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports [J].
Bertulyte, Ilma ;
Schwan, Sofie ;
Hallberg, Par .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (02) :100-138
[4]  
Bertulyte I, 2012, PHARMACOEPIDEM DR S, V21, P441
[6]   Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid [J].
Dimopoulos, M. A. ;
Kastritis, E. ;
Bamia, C. ;
Melakopoulos, I. ;
Gika, D. ;
Roussou, M. ;
Migkou, M. ;
Eleftherakis-Papaiakovou, E. ;
Christoulas, D. ;
Terpos, E. ;
Bamias, A. .
ANNALS OF ONCOLOGY, 2009, 20 (01) :117-120
[7]  
Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968
[8]   Atypical femur fractures: a review of the evidence and its implication to clinical practice [J].
Girgis, Christian M. ;
Seibel, Markus J. .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (06) :301-314
[9]   Simple solution to a common statistical problem: Interpreting multiple tests [J].
Gordi, T ;
Khamis, H .
CLINICAL THERAPEUTICS, 2004, 26 (05) :780-786
[10]   THE OPIOID AGONIST CODEINE AND ANTAGONIST NALTREXONE DO NOT AFFECT VOLUNTARY SUPPRESSION OF CAPSAICIN-INDUCED COUGH IN HEALTHY-SUBJECTS [J].
HUTCHINGS, HA ;
ECCLES, R .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (04) :715-719